Livepeer Q1 2026 network usage reaches all-time high
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma
GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.
Germany's DAX 40 fell to 25,200 points, down 0.8% in 24 hours
Borr Drilling Divests Mexican Oil Drilling Joint Ventures
Altares says French firms cut average payment delays to 12.3 days in H1 2026
Crypto prices
More
